Saccharomyces boulardii CNCM I-745 is scientifically proven to treat, prevent and recover from diarrhea

Saccharomyces boulardii CNCM I-745 is the first yeast probiotic identified¹, and has been used as a probiotic in medicine for more than 56 years.

Because of its long history, the clinical evidence of the efficacy of S. boulardii CNCM I-745 has been demonstrated for a number of diarrheal syndromes associated with an imbalance of gut microbiota¹, and is prescribed for the prevention and treatment of diarrhea in adults and children for :

• Acute infectious diarrhea – viral or bacterial² ;
• Antibiotic-associated diarrhea² ;
• Gastrointestinal side effects associated with Helicobacter pylori eradication therapy² ;
• Recurrent Clostridium difficle disease following antibiotic treatment.²

Evidence of Saccharomyces boulardii CNCM I-745 for the treatment of acute diarrhea

In children, clinical studies have demonstrated that the administration of S. boulardii CNCM I-745 with standard therapy for acute diarrhea (oral rehydration solution and zinc) significantly reduces the duration of acute diarrhea by 2.1 days.³ In hospitalized and outpatients children, the duration of diarrhea was reduced within 48 hours of receiving S. boulardii CNCM I-745.⁴

An analysis of 22 clinical trials demonstrated that the duration of acute diarrhea in children was reduced by 19.7 hours compared to control patients who did not receive S. boulardii CNCM I-745.⁵

In adults (>18 years) with acute diarrhea, S. boulardii CNCM I-745 has been shown to significantly reduce the frequency of acute diarrhea after 48 hours of treatment.⁶

The first randomized-controlled trial to investigate the administration of S. boulardii CNCM I-745 to prevent the development of antibiotic-associated diarrhea (ADD) in children demonstrated that the risk was reduced by 80%.⁷

Analysis of 21 studies investigating S. boulardii CNCM I-745 treatment to prevent AAD in adults and children demonstrated that there was a 53% reduction in the risk of developing AAD.⁸

Evidence of Saccharomyces boulardii CNCM I-745 for the prevention of H. pylori eradication therapy-associated gastrointestinal side effects

Antibiotic treatment, which is part of Helicobacter pylori eradication therapy, is associated with multiple side effects including diarrhea. In adults receiving eradication therapy, no patient administered S. boulardii CNCM I-745 experienced diarrhea compared with 9,3% (p = 0.028) of control patients.⁹ An analysis of 25 clinical studies assessing the incidence of eradication therapy-associated side effects in adults receiving S. boulardii CNCM I-745 reported a 53% reduction in side effects, including 71% of diarrhea.¹⁰ A second study that analysed 18 clinical studies in both adults and children demonstrated that the incidence of side effects in patients receiving S. boulardii CNCM I-745 was 18.1% compared to 35.2% for patients only receiving eradication therapy (p <0.00001).¹¹ In particular, S. boulardii significantly reduced the incidence of diarrhea by 67% (p <0.00001).¹¹

Evidence of Saccharomyces boulardii CNCM I-745 for the prevention of recurrent Clostridium difficile infection

Recurrent C. difficile infection is a common consequence of antibiotic therapy. In a study of adult patients, S. boulardii CNCM I-745 significantly reduced the risk of recurrent C. difficile disease (CDD) by 57% compared to control patients.¹² This was later confirmed in another study that demonstrated the risk of CDD recurrence was reduced by 66.6% compared to control patients.¹³

An analysis of clinical studies conducted over 28 years demonstrated a significant reduction in the risk of recurrent CDD associated with AAD by 63% with S. boulardii CNCM I-745 treatment.¹⁴

Therefore, there are extensive clinical studies performed that support the indicated use of S. boulardii CNCM I-745 to treat, prevent and recover from diarrhea.